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As part of our interest into the bioinorganic chemistry of gallium, gallium(III) complexes of the azole ligands 2,1,3-
benzothiadiazole (btd), 1,2,3-benzotriazole (btaH), and 1-methyl-4,5-diphenylimidazole (L) have been isolated. Reaction of btaH
or btd with GaBr3 or GaCl3 resulted in the mononuclear complexes [GaBr3(btaH)2]( 1) and [GaCl3(btd)2]( 2), respectively, while
treatment of GaCl3 with L resulted in the anionic complex (LH)2[GaCl4]( 3). All three complexes were characterized by single-
crystalX-raycrystallographyandIRspectroscopy,whiletheirantiproliferativeactivitieswereinvestigatedagainstaseriesofhuman
and mouse cancer cell lines.
1.Introduction
The coordination chemistry of gallium(III) has become an
area of increasing research activity due to its relevance with
both materials science [1–6] and biomedical developments
[7–21]. In the area of materials science, for example,
complex [Ga2(saph)2q2], where saph2− is the Schiﬀ-base
ligand bis(salicylidene-o-aminophenolate)(-2) and q− is 8-
quinolinate(-1), is a very good candidate as a novel electron-
transportingandemittingmaterialfororganiclight-emitting
diodes (OLEDs) [4]. [Gaq3] is also a promising electrolumi-
nescence (EL) material, exhibiting higher power eﬃciency
than the aluminum analogue, [Alq3][ 5, 6]. The biologi-
cal interest of gallium(III) complexes originates from the
incorporation of gallium(III) radionuclides (67Ga3+, 68Ga3+)
into diagnostic radiopharmaceuticals [7]. In addition, the
gallium salts GaCl3 and Ga(NO3)3 as well as few gallium(III)
complexes [8–19] have exhibited antitumour activity, while
Ga(NO3)3 and some GaCl3/L complexes (L = various azoles)
showed in vitro anti-HIV (HIV = human immunodeﬁciency
virus) activity [20]. The biological activity of gallium(III)
complexes has often been attributed to the fact that gal-
lium(III) is the diamagnetic biological mimic of iron(III)
[21]. It is worth mentioning that [Gaq3], which is of current
interest in materials science [5, 6], is also being evaluated
in clinical trials, along with other Ga(III) complexes, such
as gallium maltolate [tris(3-hydroxy-2-methyl-4H-pyran-4-
onato)gallium(III)], for anticancer activity [22–24].
Following our interest in the coordination chemistry
of gallium(III) [25–31] which is focused on the synthesis,
structural characterization, physical/spectroscopic study and
evaluation of the biological (antitumour and antiviral)
activity of Ga(III) complexes with biologically relevant
and nonrelevant ligands, we report herein the synthesis,2 Bioinorganic Chemistry and Applications
structural characterization, and antiproliferative activity of
three gallium complexes based on the azole ligands 2,1,3-
benzothiadiazole (btd), 1,2,3-benzotriazole (btaH), and 1-
methyl-4,5-diphenylimidazole (L).
2. Experimental
2.1. Reagents and Physical Measurements. All manipulations
were performed under a dinitrogen atmosphere, using
standard inert atmosphere techniques and puriﬁed solvents
unless otherwise noted. All other chemicals were purchased
from commercial sources and used without further puriﬁca-
tion. L was synthesized as described elsewhere [32]. Micro-
analyses (C, H, and N) were performed by the University of
IoanninaMicroanalyticalLaboratoryusinganEA1108Carlo
Erba analyzer. IR spectra (4000–450cm−1)w e r er e c o r d e do n
a Perkin-Elmer 16 PC spectrometer with samples prepared
as KBr pellets. Far-IR spectra (500–50cm−1)w e r er e c o r d e d
on a Bruker IFS 113v FT spectrometer as polyethylene
pellets.
2.2. Compound Preparation
2.2.1. Preparation of [GaBr3(btaH)2]( 1).As o l u t i o no f
GaBr3 (0.3g, 0.9mmol) in 3ml of toluene/diethyl ether
(80:20,v/v)wasaddeddropwisetoastirredsolutionofbtaH
(0.3g, 2.5mmol) in toluene (20ml). The resultant solution
was reﬂuxed for about 3 hours and then left undisturbed at
room temperature. Upon standing, X-ray quality colorless
crystals of 1 formed over a period of 3 days. The crystals
werecollectedbyﬁltration,washedwithtolueneanddried in
vacuum.Yield:0.31g(63%);Anal. Calc.forC12H10N6Br3Ga:
C, 26.32; H, 1.84; N, 15.34. Found: C, 26.28; H, 1.82; N,
15.33%.SelectedIRdata(cm−1):3238m[ν(N–H)],1222mb
[ν(N=N)], 1116s [ν(N–N)], 291s [ν(Ga–Br)], and 224w
[ν(Ga–N)].
2.2.2. Preparation of [GaCl3(btd)2]( 2). As o l u t i o no fG a C l 3
(0.25g, 1.40mmol) in 5ml of toluene/diethyl ether (80:20,
v/v) was added dropwise to a stirred solution of btd (0.6g,
4.4mmol) in toluene/diethyl ether (60:40, v/v) (10ml).
The resultant solution was reﬂuxed for about 2 hours and
then left undisturbed at −10◦C. Upon standing at low
temperature for several days, X-ray quality yellowish crystals
of 2 formed. The crystals were collected by ﬁltration, washed
with diethyl ether and dried in vacuum. Yield: 0.60g (95%);
m.p.: 112◦C. Anal. Calc. for C12H8N4S2Cl3Ga: C, 32.14;
H, 1.80; N, 12.49. Found: C, 32.13; H, 1.78; N, 12.49%.
Selected IR data (cm−1): 1612s and 1528s [ν(C=C)], 1482s
[ν(C=N)], 961m and 922s [ν(S–N)], 382s [ν(Ga–Cl)], and
207w [ν(Ga–N)].
2.2.3. Preparation of (LH)2[GaCl4]Cl (3).As o l u t i o no f
GaCl3 (0.2g, 1.13mmol) in 5ml of toluene/diethyl ether
(80:20, v/v) was added dropwise to a stirred mixture of
L (0.6g, 2.6mmol) in diethyl ether (1ml). The resultant
mixture was stirred until a clear yellowish solution was
obtained.Slowevaporationoftheresultantsolutionaﬀorded
a microcrystalline solid. The solid was collected by ﬁltration,
washed with toluene and diethyl ether, and dried in vacuum.
The product was recrystallised three times from toluene to
give crystals of 3 suitable for X-ray structural analysis. The
crystals were collected by ﬁltration, washed with toluene
and dried in vacuum. Yield: 0.18g (45%); Anal. Calc. for
C32H30N4Cl5Ga: C, 53.56; H, 4.21; N, 7.81. Found: C, 53.36;
H, 4.17; N, 7.78%. Selected IR data (cm−1): 3146–2620 sb
[ν(N–H)], 1622m [ν(C=N)], 1578w [ν(C=C)], and 369s
[ν(Ga–Cl)].
2.3. Single-Crystal X-Ray Crystallography. Crystals of 1 and
2 were mounted in air, while crystals of 3 were mounted
in air and covered with epoxy glue. Diﬀraction measure-
ments for 1 and 2 were made on a Crystal Logic Dual
Goniometer diﬀractometer using graphite-monochromated
Mo radiation, while those for 3 were made on a P21
Nicolet diﬀractometer using graphite-monochromated Cu
radiation. Complete crystal data and parameters for data
collection and processing are reported in Table 1. Unit
cell dimensions were determined and reﬁned by using the
angular settings of 25 automatically centred reﬂections in the
ranges 11 < 2θ<23
◦ for 1 and 2 and 22 < 2θ<54
◦ for
3. Three standard reﬂections monitoring every 97 reﬂections
showed less than 3% variation and no decay. Lorentz,
polarizationandψ-scan(onlyfor1)correctionswereapplied
using CRYSTAL LOGIC software. The structures were solved
bydirectmethodsusingSHELXS-86[33]andr eﬁnedb yfull-
matrix least squares techniques on F2 with SHELXL-97 [34].
All hydrogen atoms were located by diﬀerence maps and
reﬁned isotropically, except those on the methyl groups of
3 which were introduced at calculated positions as riding on
bonded atoms. For all the three structures, all nonhydrogen
atoms were reﬁned using anisotropic thermal parameters.
2.4. In Vitro Cytotoxic Activity
2.4.1. Test Substances. All test substances (complexes 1, 2,
and 3) were diluted in methanol at a concentration of
200mM. Final concentration of methanol in culture was
always less than 0.5%, a concentration that produced no
eﬀects on cell growth and proliferation, as was experimen-
tally conﬁrmed.
2.4.2. Cell Lines. Cell lines used were HeLa [35]( h u m a n
cervical cancer), OAW-42 [36] (human ovarian cancer),
HT29 [37] (human colon cancer), MCF-7 [38]( h u m a n
breast cancer), T47D [39] (human breast cancer), and L929
(929 is a clone isolated [40] from the parental strain L
derived from normal subcutaneous areolar and adipose
tissues of a mouse [41]). Cells were grown as monolayer
cultures in T-75 ﬂasks (Costar), were subcultured twice
aw e e ka t3 7 ◦C in an atmosphere containing 5% CO2
in air and 100% relative humidity. Culture medium used
was Dulbecco’s modiﬁed Eagle’s medium (DMEM, Gibco
Glasgow, UK), supplemented with 10% Fetal Bovine Serum
( F B S ,G i b c o ,G l a s g o w ,U K ) ,1 0 0 μg/ml streptomycin and
100IU/ml penicillin.Bioinorganic Chemistry and Applications 3
2.4.3. Cell Growth and Proliferation Assays. Adherent cells at
a logarithmic growth phase were detached by addition of
2-3ml of a 0.05% trypsin (Gibco, 1:250) −0.02% EDTA
mixture and incubation for 2–5 min at 37◦C. Cells were
plated (100μl per well) in 96-well ﬂat-bottom microtiter
plates (Costar-Corning, Cambridge) at a density of 5,000
(HeLa and L929) or 10,000 (HT-29, OAW-42, MCF-7 and
T47D) cells per well. Cells were left for 24 h at 37◦Ct o
resume exponential growth. An equal volume (100μl) of
either complete culture medium (control wells), or twice
the ﬁnal substance concentration diluted in complete culture
medium, was added 24 h later. Six replicate wells for each
concentration were used for the sulforhodamine B (SRB)
assay and three replicate wells for the bromodeoxyuridine
(BrdU) assay. Background control wells (n = 8), containing
thesamevolumeofcompleteculturemedium,wereincluded
in each experiment. Cell growth or DNA-synthesis was
evaluated 48 h later by means of the SRB or BrdU assays. All
experiments were performed at least twice.
2.4.4. SRB Assay. The SRB assay was carried out by a
modiﬁcation [42] of the previously reported method [43]. In
brief, culture medium was aspirated prior to ﬁxation using a
microplate-multiwash device (Tri-Continent Scientiﬁc, Inc.
Grass Valley, CA) and 50μl of 10% cold (4◦C) TCA were
gently added to the wells. Microplates were left for 30 min at
4◦C, washed 5 times with deionized water and left to dry at
room temperature for at least 24 hr. Subsequently, 70μl0 . 4 %
(w/v) sulforhodamine B (Sigma) in 1% acetic acid solution
were added to each well and left at room temperature for
20 min. SRB was removed and the plates were washed 5
times with 1% acetic acid before air drying. Bound SRB was
solubilized with 200μl1 0m Mu n b u ﬀered Tris-base solution
(E. Merck, Darmstadt, Germany) and plates were left on a
plate shaker for at least 10 min. Absorbance was read in a 96-
well plate reader (Anthos-2001, Anthos labteck instruments,
A-5022, Salzburg) at 492nm subtracting the background
measurement at 620nm. The test optical density (OD) value
was deﬁned as the absorbance of each individual well, minus
the blank value (“blank” is the mean optical density of
the background control wells, n = 8). Mean values and
CV from six replicate wells were calculated automatically.
Results were expressed as the “survival fraction” (sf), derived
from the following equation: sf = ODx/ODc, (where ODx
and ODc represent the test and the control optical density,
resp.).
2.4.5. BrdU Assay. DNA-synthesis was estimated by the
BrdU assay [44] using a standard colorimetric ELISA
(Boehringer Mannheim). After 47h exposure to test sub-
stances, cells were incubated at 37◦C for further 60
min in the presence of 10μM BrdU. Subsequently, cells
were ﬁxed with an ethanol-containing ﬁxative, an anti-
BrdU mouse monoclonal antibody conjugated with per-
oxidase was added and plates were incubated at 37◦C
for 60 min. After washing, peroxidase substrate (tetram-
ethylbenzidine) was added, the reaction was stopped 10
min later by 1M H2SO4 and absorbance was read at
450nmsubtractingthebackgroundmeasurementat620nm.
Results from each triplicate well (ODBrdUx/ODBrdUc)
were divided by the results of a parallel experiment
estimated with the SRB assay (ODSRBx/ODSRBc) and
they were expressed as the ”DNA synthesis fraction”
(fDNA) (derived from the following equation: fDNA =
(ODBrdUx×ODSRBc)/(ODBrdUc×ODSRBx), where ODx
and ODc represent the test and the control optical density
resp.), resulting in an estimation of the DNA synthesis per
cell number.
2.4.6. Cell Cycle Analysis by Flow Cytometry. For cell cycle
experiments 1.5 × 106 (HeLa and L929) or 2.5 × 106
(HT-29, OAW-42, MCF-7 and T47D) cells were seeded
in 75cm2 ﬂasks and left for 24h in incubator to resume
exponential growth. Cells were exposed to test substances
(at concentrations that produced 50% inhibition of cell
growth—estimated by the SRB assay) and after 48h they
were harvested (using trypsin/EDTA as above), washed in
PBS and counted in a hemocytometer chamber; 3×106 cells
were resuspended in 125μl cold “Saline GM” (g/L: glucose
1.1; NaCl 8.0; KCl 0.4; Na2HPO4·12H2O 0.39; KH2PO40.15;
and0.5mMEDTA)followedbytheadditionof375μlof95%
nondenatured, ice-cold ethanol [45] .C e l l sw e r ek e p ti n4 ◦C
foramaximumperiodof3days(short-termstoragedoesnot
alter results, as was experimentally conﬁrmed) until analysis
was performed.
For cell cycle analysis a 10% of standard chicken ery-
throcyte nuclei were added as a control. The samples were
processedinaDNA-preparationEpicsWorkstation(Coulter,
El). By this method the content of cellular DNA is assessed
using Propidium Iodide [46, 47]. To avoid an increased
signalbystainingartifactondoublestrandedRNA,cellswere
digested with DNase-free RNase A [48].
Cellular DNA content was measured using an Epics
II ﬂow cytometer (Coulter, El). The ﬂuorescent signals
from 10,000–20,000 cells were collected and the result was
displayed as a frequency-distribution histogram (DNA his-
togram). The mean channel, cell count, standard deviation
(SD), coeﬃcient of variation (CV), DNA index (DI), and
cell cycle distribution were calculated for each sample using
the Multicycle Cell Cycle Analysis Software (Phoenix Flow
Systems Inc.). Care was taken to exclude any doublets or cell
debris noise from the assessment.
3. Results and Discussion
3.1. Brief Synthetic Comments. Complexes 1 and 2 were
preparedbythesimplereactionsofGaBr3 orGaCl3 andbtaH
or btd in toluene/diethyl ether under nitrogen employing
1:3 molar ratios, respectively. A similar reaction involving
GaCl3 and btaH has yielded [GaCl3(btaH)2][ 25]. An
1:1 complex of GaCl3/btaH has also been isolated and
structurally characterized [25]. An attempt to isolate the
1:1 GaBr 3/btaH complex was unsuccessful resulting in 1
in a lower yield. Complex 2 is also the only product
resulting from the GaCl3/btd reaction mixtures in various
molar ratios. Complex 3 might be regarded as a product of4 Bioinorganic Chemistry and Applications
Table 1: Crystallographic data for complexes [GaBr3(btaH)2]( 1), [GaCl3(btd)2]( 2), and (LH)2[GaCl4]Cl (3).
12 3
Empirical formula C12H10N6Br3Ga C12H8N4S2Cl3Ga C32H30N4Cl5Ga
Formula weight 547.68 448.42 717.60
Crystal colour, habit Colourless, prism Colourless, prism Colourless, prism
Crystal dimensions (mm) 0.15 ×0.25 ×0.40 0.20 ×0.25 ×0.40 0.15 ×0.15 ×0.35
Crystal system Monoclinic Monoclinic Triclinic
Space group I2/a C2/c P −1
a (˚ A) 16.797(10) 12.098(11) 10.2358(10)
b (˚ A) 7.058(4) 7.525(6) 14.9649(16)
c (˚ A) 14.276(9) 18.968(16) 12.2350(11)
α (◦) 90 90 69.235(4)
β (◦) 106.60(2) 107.65(3) 86.879(3)
γ (◦) 90 90 74.939(4)
V (˚ A3) 1621.9(17) 1646(2) 1690.7(3)
Z 44 2
Dcalc (g/cm−3) 2.243 1.810 1.410
F(000) 1040 888 732
μ (mm−1) 9.091 2.411 4.966
Radiation (λ, ˚ A) 0.71073 0.71073 1.54180
Temperature (K) 298 298 298
Scan mode θ-2θθ -2θθ -2θ
Scan speed (◦ min−1) 3.5 4.2 4.5
Scan range (◦)2 . 3 + α1α2 separation 2.4 + α1α2 separation 2.25 + α1α2 separation
θ range (◦) 2.53–25.00 2.25–24.99 3.67–61.97
hkl ranges
0t o1 9 −14 to 13 −10 to 9
0t o8 −8t o0 −14 to 17
−16 to 16 0 to 22 0 to 14
Reﬂections collected 1486 1499 4586
Independent reﬂections (Rint) 1430 (0.0250) 1450 (0.0219) 4368 (0.0149)
No of reﬁned parameters 121 118 479
Observed reﬂections [I>2σ(I)] 1293 1341 3740
GOF (on F2 ) 1.143 1.062 1.087
Final R indicesa[I>2σ(I)] R1 = 0.0332 R1 = 0.0301 R1 = 0.0345
wR2 = 0.0903 wR2 = 0.0826 wR2 = 0.0830
R indicesa(all data) R1 = 0.0375 R1 = 0.0333 R1 = 0.0448
wR2 = 0.0930 wR2 = 0.0852 wR2 = 0.1009
Largest diﬀerence peak and hole (e ˚ A−3) 0.681 and −1.263 0.546 and −0.387 0.418 and −0.493
aDeﬁned as: R1 = Σ(|Fo|− |Fc|)/Σ(|Fo|), wR2 ={ Σ[w(F2
o −F2
c )]/Σ[w(F2
o)
2]}
1/2
,w h e r ew = 1/[σ2(F2
o)+(aP)2 +( bP)] with P = [max(F2
o,0)+2F2
c ]/3.
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Figure 1: A labeled ORTEP plot of [GaBr3(btaH)2]( 1) showing 30% probability ellipsoids.Bioinorganic Chemistry and Applications 5
(a)
(b)
Figure 2: The hydrogen-bonded tape of [GaBr3(btaH)2]( 1) running parallel to a axis (a) and the stacking of the tapes (b).
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Figure 3: A labeled ORTEP plot of [GaCl3(btd)2]( 2) showing 30% probability ellipsoids.
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Figure 4: The stacking of the [GaCl3(btd)2] molecules in 2.6 Bioinorganic Chemistry and Applications
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Figure 5: A labeled ORTEP plot of the asymmetric unit of (LH)2[GaCl4]Cl (3), showing 30% probability ellipsoids.
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Figure 6: The intermixture of the weak interactions between the anions and the cations in 3.M o s to ft h eh y d r o g e na t o m sh a v eb e e no m i t t e d
for clarity.
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Figure 7: Dose-eﬀect plots of complex 1 against a panel of human
and mouse cancer cell lines 24h after the administration of the
agents. Cytotoxicity was estimated via SRB assay (each point
represents a mean of six replicate wells).
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Figure 8: Dose-eﬀect plots of complex 2 against a panel of human
and mouse cancer cell lines 24h after the administration of the
agents. Cytotoxicity was estimated via SRB assay (each point
represents a mean of six replicate wells).Bioinorganic Chemistry and Applications 7
Table 2: Selected interatomic distances (
 
˚ A) and angles (◦)f o r
complex 1.
Ga–N(3)  2.212(3) N(3)–N(2) 1.314(5)
Ga–N(3) 2.212(3) N(3)–C(8) 1.378(6)
Ga–Br(2) 2.3204(17) N(1)–N(2) 1.323(5)
Ga–Br(1)  2.3436(11) N(1)–C(9) 1.344(6)
Ga–Br(1) 2.3436(11) N(1)–HN1 0.89(7)
N(3) –Ga–N(3) 176.2(2) Br(2)–Ga–Br(1)  123.81(3)
N(3) –Ga–Br(2) 88.08(10) N(3) –Ga–Br(1) 90.13(10)
N(3)–Ga–Br(2) 88.08(10) N(3)–Ga–Br(1) 92.01(10)
N(3) –Ga–Br(1)  92.01(10) Br(2)–Ga–Br(1) 123.81(3)
N(3)–Ga–Br(1)  90.13(10) Br(1) –Ga–Br(1) 112.39(6)
( )Symmetry code: −x +1 /2, y, −z +1.
Table 3: Selected interatomic distances (
 
˚ A) and angles (◦)f o r
complex 2.
Ga–Cl(1) 2.171(2) N(3)–C(8) 1.357(4)
Ga–Cl(2)  2.180(1) N(3)–S(2) 1.631(3)
Ga–Cl(2) 2.180(1) S(2)–N(1) 1.601(3)
Ga–N(3) 2.201(3) N(1)–C(9) 1.336(5)
Ga–N(3)  2.201(3)
Cl(1)–Ga–Cl(2)  120.24(4) Cl(2) –Ga–N(3)  88.34(9)
Cl(1)–Ga–Cl(2) 120.24(4) Cl(2)–Ga–N(3)  90.45(9)
Cl(2) –Ga–Cl(2) 119.52(7) N(3)–Ga–N(3)  177.58(12)
Cl(1)–Ga–N(3) 91.21(6) C(8)–N(3)–S(2) 107.52(19)
Cl(2) –Ga–N(3) 90.45(9) C(8)–N(3)–Ga 130.00(19)
Cl(2)–Ga–N(3) 88.34(9) S(2)–N(3)–Ga 122.41(14)
Cl(1)–Ga–N(3)  91.21(6) N(1)–S(2)–N(3) 99.20(15)
( )Symmetry code: −x +1 , y, −z +1/2.
Table 4: Selected interatomic distances (
 
˚ A) and angles (◦)f o r
complex 3.
Ga–Cl(3) 2.152(1) C(2)–N(3) 1.309(5)
Ga–Cl(4) 2.166(1) N(3)–C(4) 1.389(4)
Ga–Cl(1) 2.171(1) N(11)–C(22) 1.320(5)
Ga–Cl(2) 2.173(1) N(11)–C(25) 1.392(4)
N(1)–C(2) 1.320(5) N(11)–C(38) 1.463(4)
N(1)–C(5) 1.393(4) C(22)–N(13) 1.318(5)
N(1)–C(18) 1.460(4) N(13)–C(24) 1.383(4)
Cl(3)–Ga–Cl(4) 110.87(5) Cl(3)–Ga–Cl(2) 110.55(5)
Cl(3)–Ga–Cl(1) 110.17(5) Cl(4)–Ga–Cl(2) 108.62(5)
Cl(4)–Ga–Cl(1) 109.49(5) Cl(1)–Ga–Cl(2) 107.05(5)
hydrolysis which is pretty usual in Ga(III) chemistry in water
or water containing solutions [30].
3.2. IR Spectra. The IR spectrum of 1 exhibits a medium
intensity band at ∼3238cm−1, assignable to ν(N–H). The
bands at 1222 and 1116cm−1 are attributed to the ν(N=N)
andν(N–N)vibrations,respectively,andareshiftedtohigher
wavenumbers with respect to the spectrum of the free
Table 5: Cell cycle distribution of cells before (control) and after
4 8he x p o s u r et oI C 50 values of 3 as determined by ﬂow cytometry.
G1 (%) S (%) G2 (%)
HeLa Control 62.0 26.6 11.4
3 57.7 35.0 7.3
T47D Control 57.4 28.4 14.3
3 58.1 34.3 7.6
HT29 Control 43.5 39.4 17.1
3 53.2 24.6 22.2
MCF-7 Control 42.0 50.4 7.6
3 54.1 35.4 10.5
OAW-42 Control 47.8 11.3 40.9
3 87.2 11.8 1.0
L929 Control 42.0 48.0 10.0
3 43.0 23.6 33.4
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Figure 9: Dose-eﬀect plots of complex 3 against a panel of human
and mouse cancer cell lines 24h after the administration of the
agents. Cytotoxicity was estimated via SRB assay (each point
represents a mean of six replicate wells).
ligand (1208 versus and 1084m, resp.). The IR spectrum
of 2 exhibits three strong intensity bands at 1612, 1528
and 1482cm−1 assignable to stretching carbon-carbon and
carbon-nitrogen vibrations. These bands are not shifted
signiﬁcantly with respect to the spectrum of the free ligand
[1608w, 1518s and 1476 s]. The bands at 950 and 916cm−1
in the spectrum of btd, which are assigned to the ν(S–
N) mode, have been shifted to higher wavenumbers in the
spectrum of 2 [961 and 922cm−1]. A set of broad bands in
the region of 3146–2620cm−1 in the spectrum of 3 can be
assigned to the ν(N–H) of the protonated ligand, LH+.T h e
ν(C=N)andν(C=C)ofthefreeLat1602and1575cm−1 have
shifted to 1622 and 1578cm−1 in the spectrum of 3 due to
protonation.
The far-IR spectra of all three complexes are expected to
show one Ga–X (X = Cl or Br) stretching mode [25]a n d
these modes appear at 291s [ν(Ga–Br) in 1], 382s [ν(Ga–
Cl) in 2], and 369s [ν(Ga–Cl) in 3]. The far-IR spectra
of complexes 1 and 2 exhibit one more band at 224 and
207cm−1, respectively, which are attributed to the ν(Ga–N)
mode [25].8 Bioinorganic Chemistry and Applications
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Figure 10: DNA synthesis inhibition of human and mouse cancer
cell lines 48h after the administration of complex 3.
3.3. Description of Structures. An ORTEP diagram of 1
is shown in Figure 1. Selected bond distances and angles
are given in Table 2.C o m p l e x1 is isostructural with
[GaCl3(btaH)2][25].Itsstructureconsistsofthemonomeric
discrete [GaBr3(btaH)2] units. The gallium coordination
geometry is trigonalbipyramidal with the bromo ligands
deﬁning the equatorial plane. There is a two-fold crystal-
lographic axis along the Ga–Br2 bond. The Ga–N bond
length in complex 1 [2.212(3) ˚ A] is longer than that of
[GaCl3(btaH)2] [2.169(2) ˚ A]. The dihedral angle between
the best planes of the btaH molecules is 10.90 ˚ A and is
larger than that of [GaCl3(btaH)2][ 7 . 4 ◦]. The N1 pro-
t o ni sh y d r o g e nb o n d e dt oa t o mB r 1o fan e i g h b o r i n g
molecule [N1···Br1  (1 − x, −y,1− z) 3.425(4) ˚ A,
HN1···Br1  2.64(7) ˚ A and N1–HN1···Br1  149(6)◦]c r e -
ating a hydrogen-bonded tape running parallel to the a axis
(Figure 2). These tapes are hold together in the crystal lattice
through π-π interactions. Those interactions form between
the phenyl groups of the coordinated btaH molecules of
neighboring tapes [centroid···centroid  (1 − x,0 .5+y,
1.5 − z) 3.658(4) and 3.906(4) ˚ A] (Figure 2).
Complex 2 crystallizes in the monoclinic space group
C2/c. An ORTEP diagram of 2 is shown in Figure 3, while
selected bond distances and angles are listed in Table 3.
Its structure consists of monomeric discrete [GaCl3(btd)2]
units. The gallium coordination geometry is again trigonal-
bipyramidal with the choro ligands deﬁning the equatorial
plane. There is a two-fold crystallographic axis along the
Ga–Cl1 bond. The Ga–Cl bond lengths in complex 2
[2.171(2) and 2.180(1) ˚ A] compare favourably with those
of [GaCl3(btaH)2] [2.204(1) and 2.178(2) ˚ A]. The Ga–N
bond length in complex 2 [2.201(3) ˚ A] is longer than that of
[GaCl3(btaH)2] [2.169(2) ˚ A], but compares well with that of
1 [2.212(3) ˚ A]. The dihedral angle between the best planes
of the btd molecules is 52.51 ˚ A and is much larger than
that of 1 and [GaCl3(btaH)2] (10.90 and 7.4◦,r e s p . ) .T h e r e
appear to be intermolecular stacking interactions between
the nearly parallel btd ligands. Those interactions involve
both the thiadiazole and the phenyl groups of the btd ligands
as shown in Figure 4.
An ORTEP diagram of the asymmetric unit of 3 is
shown in Figure 5. Selected bond distances and angles are
listed in Table 4. The crystal of 3 consists of protonated
LH+ ligand cations, tetrachlorogallate(III) anions and Cl−
anions. The Ga–Cl distances in the tetrahedral [GaCl4]− ion
are in the narrow range 2.152(1)–2.173(1) A◦ with the Cl–
Ga–Cl angles varying from 107.1(1)◦ to 110.9(1)◦. These
values are similar to those observed for other complexes
containingthetetrachlorogallate(-1)ion[13,29].Thecrystal
structure of (LH)2[GaCl4]Cl is dominated by an intermix-
ture of N–H···Cl and CMe–H···π hydrogen bonds, Ga–
Cl···πazole and π-π interactions (Figure 6). The organic
moieties LH+ are connected through N–H···Cl and C–
H···πphenyl interactions to form a chain; data are as follows
N3···Cl5  (2 − x, −y,2− z) 3.088(3) ˚ A, HN3···Cl5 
2.24(4) ˚ A and N3–HN3···Cl5  160(4)◦;N 1 3 ···Cl5   (x −
1, 1 + y, z − 1) 3.066(4) ˚ A, HN13···Cl5   2.19(5) ˚ A
and N13–HN13···Cl5   177(5)◦;C 3 8 ···Centroid  (1 −
x, −y,2− z) 3.691(5) ˚ A, H38A···Centroid  2.85(1) ˚ A
and C38–H38A···Centroid  147(1)◦. The organic chains
are bridged through Ga–Cl···πazole interactions to form
layers [Cl1···Centroid   (−x,1− y,1− z) 3.455(2) ˚ Aa n d
Cl4···Centroid    (1 − x,1− y,1− z) 3.550(2) ˚ A], which
are further bridged through π-π interactions in the third
dimension [centroid···centroid  (1−x, −y,2−z) 3.778(3)
and centroid···centroid     (−x,2− y,1−z) 3.878(3)].
3.4. Antiproliferative Activity. Complexes 1 (Figure 7)a n d2
(Figure 8) had no signiﬁcant inhibition on cellular prolifer-
ation against HeLa, HT29 and OAW-42 cancer cell lines and
as m a l le ﬀect against L929 normal ﬁbroblastic cell line. In
contrast, complex 3 inhibited cellular growth of all cell lines,
with IC50 concentrations varying between 75 and 125μM
(Figure 9).
DNA synthesis was not inhibited in HT29, HeLa, MCF-7
or L929 cell lines when they were exposed to 3 at concen-
trations up to 100μM. Higher concentrations exhibited an
inhibition of DNA synthesis per cell number only in HeLa
and at a lower level in L929 cells (Figure 10).
Treatment with IC50 concentrations of 3 for 48fh had
no eﬀects on cell cycle distribution of HeLa and T47D cells
(Table 5). HT29 and MCF-7 were partially arrested at the
G1 phase, OAW-42 were arrested at the G1 phase with a
percentage of 87.2% and L929 ﬁbroblasts exhibited a partial
G2-phase arrest. However, the overall eﬀect of 3 on cell cycle
distribution (except with OAW-42 cells) was not signiﬁcant,
an observation in concert with the results of the BrdU assay,
where no inhibition of DNA-synthesis was observed.
4. Concluding Comments
Inthisstudy,threegallium(III)azolecomplexesweresynthe-
sized and structurally characterized, while their antiprolifer-
ative activities were studied. The three diﬀerent azole ligands
w e r ec h o s e ni no r d e rt ob ea b l et od r a ws t r u c t u r e - p r o p e r t i e s
relations. In two of the complexes (1 and 2) the Ga(III)
atom is in a trigonal-bipyramidal coordination environment
where the terminal azole ligands occupy the axial positions.Bioinorganic Chemistry and Applications 9
The third complex (3) consists of [GaCl4]− anions, chlorine
anions and protonated imidazole cations. From the three
complexes tested only 3 exhibited a potent anti-proliferative
activity against all cell lines tested. The order of cell lines in
respect to their sensitivity to 3 (at IC50 values) is as follows:
HeLa >MCF-7>T47D>L929>HT29>OAW-42.Complex
3 does not inhibit DNA synthesis at concentrations that exert
antiproliferative activity (IC50s) and does not produce major
disturbances in cell cycle distribution (with the exception of
OAW-42 cells that, notably, are the most resistant to its anti-
proliferative activity).
5. Supplementary Information
CCDC 717554, 717555, and 717553 contain the supplemen-
tary crystallographic data for 1, 2,a n d3. These data can be
obtainedfreeofchargefromtheCambridgeCrystallographic
Data Center via http://www.ccdc.cam.ac.uk/data request/cif.
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